Epistem signs drug discovery collaboration with Novartis
The deal will see Novartis pay Epistem US$4 million in an upfront payment and provide research funding for 2 years to identify new drug targets and therapeutics across a wide range of disease areas. Epistem will provide its stem cell expertise and drug discovery experience with Novartis’s knowledge of disease pathways and bioinformatics. Novartis will have an option to licence any drug targets in exchange for license fees, milestone payments and royalties.
Matthew Walls, Epistem CEO, commented:
"The collaboration will enable us to accelerate the development of our existing targets with a world class pharmaceutical collaborator and to jointly explore disease opportunities in regenerative medicine".
Quick facts: Genedrive PLC
Market Cap: £5.78 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Genedrive PLC named herein, including the promotion by the Company of Genedrive PLC in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE